This is week-old news, but worth repeating.
| Key blockbuster drugs about to get generic rivals | ||||
| These are blockbuster drugs, with more than $1 billion in annual global sales, set to go off patent and get generic competition in the U.S. in the next two years: | ||||
| Patent ends | Brand name | Generic name | Use/conditions treated | Made/sold by |
| Oct. 2011 | Zyprexa | olanzapine | schizophrenia/bipolar | Eli/Lilly |
| Nov. 2011 | Lipitor | atorvastatin | high cholesterol | Pfizer |
| March 2012 | Lexapro | escitalopram | depression | Forest/Labs |
| March 2012 | Seroquel | quetiapine | schizophrenia/bipolar | AstraZeneca |
| March 2012 | Avapro/Avalide | irbesartan | high blood pressure | Bristol-Myers/Sanofi |
| April 2012 | Provigil | modafinil | narcolepsy | Cephalon |
| May 2012 | Plavix | clopidogrel | clot prevention | Bristol-Myers/Sanofi |
| July 2012 | Tricor | fenofibrate | high triglycerides | Abbott |
| Aug. 2012 | Singulair | montelukast | asthma/allergies | Merck |
| Aug. 2012 | Actos | pioglitazone | diabetes | Takeda |
| Sept. 2012 | Diovan | valsartan | high blood pressure | Novartis |
| Sept. 2012 | Geodon | ziprasidone | bipolar disorder | Pfizer |
| Nov. 2012 | Lidoderm | lidocaine | pain patch | Endo |
| Dec. 2012 | Atacand | candesartan | heart failure | AstraZeneca |
| March 2013 | Lovaza | omega-3 acid | high triglycerides | GlaxoSmithKline |
| Aug. 2013 | Temodar | temozolomide | brain tumors | Merck |
| Note: Patent expiration/generic arrival dates can change due to litigation or regulatory issues.Sources: Medco Health Solutions, company websites. | ||||
